Myelodysplastic Syndromes News and Research

RSS
CTI first quarter net loss decreases 66% to $17.4 million

CTI first quarter net loss decreases 66% to $17.4 million

Targeting inflammatory pathways may lead to new therapies

Targeting inflammatory pathways may lead to new therapies

Targeted drugs should be aimed at mutations that develop early in blood cancer

Targeted drugs should be aimed at mutations that develop early in blood cancer

Array second quarter revenue increases to $23.2 million

Array second quarter revenue increases to $23.2 million

Scientists uncover critical genetic mutation in patients with MDS

Scientists uncover critical genetic mutation in patients with MDS

Novel prognostic model for patients with treatment-related MDS

Novel prognostic model for patients with treatment-related MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Celgene announces results from azacitidine Phase 1 study on AML

Celgene announces results from azacitidine Phase 1 study on AML

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Age is no longer a barrier to allogeneic stem cell transplantation

Age is no longer a barrier to allogeneic stem cell transplantation

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Close link between SF3B1 mutation and specific feature of myelodysplastic syndromes

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

G-CSF therapy does not induce chromosomal instability in healthy stem cell donors

G-CSF therapy does not induce chromosomal instability in healthy stem cell donors

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Genetic mutations in abnormal bone marrow can predict mortality of MDS patients

Genetic mutations in abnormal bone marrow can predict mortality of MDS patients